Both peptide (ghrelin, GHRP-6) and non-peptide (MK-677-related) GH secretagogues stimulated gastric motility in mice, with peptide agonists showing stronger gastroprokinetic effects — confirming gut effects across the GHS drug class.
Key findingBoth peptide (ghrelin, GHRP-6) and non-peptide GH secretagogues stimulated gastric contractions in mice in vivo and in vitro, with peptide agonists pr
What the researchers found
Both peptide (ghrelin, GHRP-6) and non-peptide GH secretagogues stimulated gastric contractions in mice in vivo and in vitro, with peptide agonists producing stronger gastroprokinetic effects — gut motility stimulation is a class effect of GHS.
Why it matters
Relevant for ghrp, gut-healing.
How the study worked
animal-study study on ghrp, gut-healing.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro.
Gut, 54(8), 1078-84
Citation
Kitazawa, T; De Smet, B; Verbeke, K; Depoortere, I; Peeters, T L. (2005). Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro.. Gut, 54(8), 1078-84.